BTIG Downgrades DexCom (DXCM) to Neutral
- Wall St stumbles as FBI to review more Clinton emails
- FBI to review more emails related to Clinton's private email use
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BTIG downgraded DexCom (NASDAQ: DXCM) from Buy to Neutral and removed its price target. Analyst Sean Lavin thinks shares are fairly valued given the stock's run.
"While we do not think shares are overvalued and could argue for a bit more upside as revenue should continue to exceed guidance in our opinion, we do feel a lot of good news is priced in, and given the historical volatility we would like more significant upside than we see at this time to maintain our Buy rating. One additional issue is investors are starting to focus on margins and profitability," said Lavin.
Shares of DexCom closed at $91.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Partners Downgrades McKesson (MCK) to Market Perform
- Jefferies Raises Price Target on Bristol-Myers Squibb (BMY) Following 3Q
- Oppenheimer Raises Price Target on Cirrus Logic, Inc. (CRUS); Reiterates Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!